Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of dose-dense rituximab-chemotherapy with or without high-dose intensification and autologous stem cell transplantation in young high-risk diffuse large B-cell lymphoma
2007-000275-42Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jan 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 6 more in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Failure-free survival at 2 years. Started Jan 2007; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2007-000275-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000275-42.